Xiagem 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscles. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control compared to monotherapy. Xiagem 2 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent are insufficient to achieve target blood glucose levels. It is essential to use this medication under medical supervision, with regular monitoring of blood glucose and renal function. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia due to Glimepiride. Patients should be advised on recognizing symptoms of hypoglycemia and the importance of adherence to prescribed dosages. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Xiagem 2 Tablet PR offers an effective therapeutic option for optimizing glycemic control in type 2 diabetes management.